Resource utilization impact of topiramate for migraine prevention in the managed-care setting

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 499-503

  Wertz, Debra A ^a   Quimbo, Ralph M ^a   Yaldo, Avin Z ^b   Rupnow, Marcia F T ^b  

^a HEALTHCORE INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cost; Headache; Migraine prophylaxis; Resource use; Topiramate

Indexed keywords

ERGOTAMINE; NON PRESCRIPTION DRUG; TOPIRAMATE; TRIPTAN DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EMERGENCY CARE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MIGRAINE; PRESCRIPTION; RETROSPECTIVE STUDY; COHORT ANALYSIS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; LONGITUDINAL STUDY; MIDDLE AGED;

ADULT; COHORT STUDIES; FEMALE; FRUCTOSE; HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MIGRAINE DISORDERS; RETROSPECTIVE STUDIES;

EID: 64249133493     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802664199     Document Type: Article

References (14)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657 (Pubitemid 32777747)
2. Clouse JC, Osterhaus JT. Health care resource use and costs associated with migraine in a managed health care setting. Ann Pharmacother 1984;28:659-664
3. Hawkins K, Rupnow MFT, Wang S. Direct cost burden of migraine among members of US employers. Poster presentation at 48th Annual Meeting of the American Headache Society, Los Angeles, CA, June 22-25, 2006.
4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-763
5. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005;45:1012-1022
6. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003; 43:171-178 (Pubitemid 36348763)
7. Silberstein SD, Feliu AL, Rupnow MFT, et al. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache 2007;47:500-510 (Pubitemid 46625259)
8. Feliu AL, Rupnow MF, Blount A, et al. Resource use associated with topiramate in migraine prophylaxis.. Am J Health Syst Pharm 2007;64:1483-1491 (Pubitemid 47077131)
9. Topamax Package Insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; Revised April 2008.
10. Silberstein SD, Neto W, Schmitt J, et al. for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology 2004;61:490-495
11. Lipton RB, Bigal ME, Diamond M, et al. on behalf of the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007:68:343-349
12. Brandes JL, Saper JR, Diamond M, et al. for the MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004:291:965-973
13. Pizzi L, Gagne JJ, Lofland JH, et al. Effect of topiramate migraine prophylaxis on work-place productivity: results from two U.S. randomized, double-blind, placebo-controlled, multicenter trials. Headache 2006;46:852
14. Diamond M, Dahlof C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023-1030